Interferon beta-1b - Bayer HealthCare Pharmaceuticals/Novartis

Drug Profile

Interferon beta-1b - Bayer HealthCare Pharmaceuticals/Novartis

Alternative Names: BAY 86-5046; Betaferon; Betaseron; Extavia; Interferon β-1b; NVF233; SH 579; ZK 157046

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Chiron
  • Developer Bayer HealthCare Pharmaceuticals; Bayer Schering Pharma; Bayer Yakuhin; Novartis
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon beta stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Multiple sclerosis
  • Discontinued Cardiomyopathies; HIV infections; Prostate cancer; Rhinovirus infections

Most Recent Events

  • 14 Dec 2016 US FDA accepts sBLA for myBETAapp™ and the BETACONNECT™ Navigator for Multiple sclerosis (relapsing-remitting) for review
  • 22 Apr 2015 US FDA accepts sBLA for interferon β-1b delivery using BETACONNECTTM for Multiple sclerosis (relapsing-remitting) for review
  • 01 Mar 2011 Bayer Schering Pharma is now called Bayer Healthcare Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top